2-methyl-8-(2,4,6-trimethyl-phenyl)-quinolin-4-ol | 204062-60-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 2-methyl-8-(2,4,6-trimethyl-phenyl)-quinolin-4-ol
• 英文别名: 2-methyl-8-(2,4,6-trimethylphenyl)-1H-quinolin-4-one
• CAS: 204062-60-2
• 化学式: C₁₉H₁₉NO
• 分子量: 277.366
• InChiKey: OUFXKYCMLGRVGL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.7
• 重原子数：
  21
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.21
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-methyl-8-(2,4,6-trimethyl-phenyl)-quinolin-4-ol 在 三氯氧磷 作用下， 生成 4-chloro-2-methyl-8-(2,4,6-trimethyl-phenyl)-quinoline
  参考文献：
  名称：

  Synthesis and SAR of 8-Arylquinolines as potent corticotropin-Releasing factor1 (CRF1) receptor antagonists

  摘要：

  A series of 4-substituted 8-aryl-2-methylquinolines 4 was designed and synthesized as highly potent antagonists for the human CRF1 receptor. This series of compounds displayed parallel SAR to other bicyclic systems such as pyrazolo[l,5-a]pyrimidines, with several compounds possessing low nanomolar binding affinity. In addition to the high potency, the basicity of this 4-aminoquinoline core may offer CRF1 antagonists with lower lipophilicity. (C) 2003 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(03)00684-x
• 作为产物：
  描述：

  2,4,6-三甲基苯硼酸 在 四(三苯基膦)钯 、 sodium carbonate 、 对甲苯磺酸 作用下， 以 二苯醚 、 苯 为溶剂， 生成 2-methyl-8-(2,4,6-trimethyl-phenyl)-quinolin-4-ol
  参考文献：
  名称：

  Synthesis and SAR of 8-Arylquinolines as potent corticotropin-Releasing factor1 (CRF1) receptor antagonists

  摘要：

  A series of 4-substituted 8-aryl-2-methylquinolines 4 was designed and synthesized as highly potent antagonists for the human CRF1 receptor. This series of compounds displayed parallel SAR to other bicyclic systems such as pyrazolo[l,5-a]pyrimidines, with several compounds possessing low nanomolar binding affinity. In addition to the high potency, the basicity of this 4-aminoquinoline core may offer CRF1 antagonists with lower lipophilicity. (C) 2003 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(03)00684-x

文献信息

• Substituted6,6-hetero-bicyclicderivatives
  申请人：——

  公开号：US20030114671A1

  公开（公告）日：2003-06-19

  This invention relates to compounds of the formula 1 wherein A, B, D, E, K, G, R 3 and R 5 are defined as in the specification, and to the pharmaceutically acceptable salts of such compounds.

  该发明涉及公式1中的化合物，其中A、B、D、E、K、G、R3和R5如规范中定义的那样，以及这些化合物的药用盐。
• SUBSTITUTED 6,6-HETERO-BICYCLIC DERIVATIVES
  申请人：PFIZER INC.

  公开号：EP0925298A1

  公开（公告）日：1999-06-30
• US6875769B2
  申请人：——

  公开号：US6875769B2

  公开（公告）日：2005-04-05
• [EN] SUBSTITUTED 6,6-HETERO-BICYCLIC DERIVATIVES<br/>[FR] DERIVES 6,6-HETERO-BICYCLIQUES SUBSTITUES
  申请人：PFIZER INC.

  公开号：WO1998008846A1

  公开（公告）日：1998-03-05

  (EN) This invention relates to compounds of formula (I), wherein A, B, D, E, K, G, R3 and R5 are defined as in the specification, and to the pharmaceutically acceptable salts of such compounds. Compounds (I) are corticotropin releasing factor (hormone) CRF (CRH) antagonists.(FR) Composés de formule (I) et sels pharmaceutiquement acceptables de ces derniers. Ces composés (I) sont des antagonistes du facteur (hormone) libérant de la corticotropine (FLC) (HLC). Dans la formule (I) A, B, D, E, K, G, R3 et R5 sont tels que définis dans la description de la demande de brevet.
• Synthesis and SAR of 8-Arylquinolines as potent corticotropin-Releasing factor1 (CRF1) receptor antagonists
  作者：Charles Q. Huang、Keith Wilcoxen、James R. McCarthy、Mustapha Haddach、Thomas R. Webb、Jian Gu、Yun-Feng Xie、Dimitri E. Grigoriadis、Chen Chen

  DOI：10.1016/s0960-894x(03)00684-x

  日期：2003.10

  A series of 4-substituted 8-aryl-2-methylquinolines 4 was designed and synthesized as highly potent antagonists for the human CRF1 receptor. This series of compounds displayed parallel SAR to other bicyclic systems such as pyrazolo[l,5-a]pyrimidines, with several compounds possessing low nanomolar binding affinity. In addition to the high potency, the basicity of this 4-aminoquinoline core may offer CRF1 antagonists with lower lipophilicity. (C) 2003 Elsevier Ltd. All rights reserved.